Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

rosis factor-alpha (TNFα), has become an appropriate therapeutic approach for refractory UC patients.[ 6 ] These biological agents have proved to be effective in inducing and maintaining remission and substantially improving the clinical course.[ 5 ] Mucosal healing (MH) is considered an additional highly significant therapeutic target to achieve long-term remission and to change the natural course of UC.[ 7 ] Colonoscopy is the gold standard in the diagnosis of mucosal healing.

also in 132,142 other papers